Level C· Early human research exploring benefitsCase Report / SeriesPubMed

Therapeutic potential of mesenchymal stem cells transplantation on traumatic facial nerve paralysis in two horses.

de Oliveira Ferreira LV., Maia L., de Andrade DGA., da Costa Kamura B., de Carvalho M., Amorim RM.

Case Report / Series on Scar, Chronic Inflammation, published in Vet Res Commun (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Vet Res Commun (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
39998709
DOI
10.1007/s11259-025-10692-1

Abstract (original English)

Cell-based therapy has emerged as a promising strategy for treating peripheral nervous system (PNS) injuries across different species. However, there is a scarcity in the literature regarding the transplantation of mesenchymal stem cells (MSCs) for treating PNS injuries in horses. This report aims to describe the therapeutic potential of equine MSC transplantation in two horses with chronic traumatic facial nerve paralysis. Both horses presented with lip ptosis and right deviation of the nostril and upper lip, being clinically diagnosed with left facial nerve paralysis. Due to the refractoriness to conventional anti-inflammatory treatments, cell-based therapy was chosen. One horse received an autologous transplant of equine bone marrow-derived MSCs (EqBM-MSCs) four months after the traumatic event, while the other underwent three transplants of allogeneic equine adipose tissue-derived MSCs (EqAT-MSCs) at 30-day intervals, starting two months after the injury. All transplants were performed at three different sites around the facial nerve, at the level of bifurcation of the buccal branch in both horses. Physical and neurological assessments revealed significant clinical recovery within three months for the first horse and four months for the second. These findings demonstrated that equine MSCs transplants have great therapeutic potential for chronic traumatic facial nerve paraly

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsFacial Nerve InjuriesFacial ParalysisHorse DiseasesHorsesMesenchymal Stem Cell TransplantationMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research